1. We contribute to the UN’s Global Sustainability Goal for good health and well-being
Healthcare associated infections (HAIs) are a growing problem and constitute a major threat to global public health. HAIs are infections that patients acquire in hospital care or when seeking other kinds of healthcare. These infections often occur as a result of medical or surgical procedures.
HAIs result in longer hospital stays, greater suffering for patients and their relatives and more antibiotics being prescribed, which is contributing to higher antibiotic resistance. According to WHO, antibiotic resistance threatens the UN’s goal to end the epidemics of, for example, AIDS, tuberculosis and malaria by 2030.
Our technology forms an important link in the value chain for healthcare associated infections, as it reduces the risk of infections when using medical devices.
Antibiotic resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress.
Tedros Adhanom Ghebreyesus, Director General of WHO
2. Our technology is effective and safe
Bactiguard’s technology consists of a unique coating that is applied to medical devices. The coating results in less bacteria attaching to the surface. This reduces the risk of biofilm formation that causes, for example, catheters-assoicated urinary tract infections.
We have been developing our unique coating of noble metals for more than 30 years. We performed our first clinical tests back in 1986, and in 1994 a urinary catheter with Bactiguard’s coating was registered by the FDA in the USA. To date there are no reported adverse events related to the technology. Our technology is effective, tissue-friendly and safe for the patient.
We protect our technology
The current patent is in force in the USA until 2027 and until 2029 in other countries. Patent applications have been submitted for a new generation of technology. The patent comprises a combination of noble metals deposited on the surface of a product, the application process and most of the medical devices and implants on which the technology can be applied.
Both process expertise and pre-treatment tailored to the base material are required to ensure that the coating attaches to the products.
The recipe is a valuable and well-kept trade secret.
3. Clinical evidence
Clinical studies are important in verifying how effective our technology is and supporting a wider use of our products. These studies also increase our knowledge of the problems associated with HAIs and generate more data about our products. Clinical evidence makes it easier for us to secure regulatory approval for new products and the speed of these approval processes is an important competitive advantage. Our clinical studies and knowledge of approval processes are also important when developing our distribution network and negotiating license agreements.
Our studies are performed in Sweden and abroad in collaboration with physicians, nurses and other healthcare professionals. All studies are designed in accordance with international and local laws, rules and ethical principles. They are reviewed and approved by ethical review boards and relevant authorities.
- 200 million catheters with our coating have been used for 25 years
- 100,000 patients in more than 40 clinical studies
- No adverse events related to the coating have been reported
4. Significant market potential
We see many potential applications for our technology through our license business and by developing our own products.
The CE mark in December 2018 opened up a major potential market for us. Our technology has now been approved in Europe for use on metal implants that will remain in a patient’s body over a long period of time, sometimes for the rest of their life. This has opened up the market for orthopaedic implants, worth over USD 50 billion.
5. Clear growth strategy
We are a growth company with a clear strategy for growing our business. This strategy involves developing our own product portfolio and establishing new license agreements for different areas of use. Read more about growth strategy
6. Unique market position
We have a unique position due to our effective and tissue-friendly technology. We have also gained know-how about the coating process as well as regulatory approval processes for more than 20 years which are key advantages when expanding our business.
Through license and distribution agreements we are today present on many markets throughout the world. The USA and China represent our largest markets. Read more about our business model
7. Broad product portfolio for infection prevention
Our product portfolio comprises urinary catheters, endotracheal tubes and central venous catheters. Using these products reduces the risk of infections in the areas that are most often subject to HAIs, namely the urinary tract, the respiratory tract and the bloodstream. About two third of all HAIs occur in these areas, with medical devices responsible for a high proportion of these infections.
The acquisition of Vigilenz broadens our product portfolio with surgical sutures, mesh, disinfectants, wound wash, dressings and orthopaedic trauma implants. One Vigilenz product which we consider to have significant potential is Hydrocyn® aqua, for hand and surface disinfection, advanced care of acute and chronic wounds. This product is CE marked and has been registered by the FDA in the USA.
8. License business
We have five license agreements and are in discussions with other leading medical device companies throughout the world. The goal is to sign 1-2 new license agreements per year.
Bactiguard’s technology can be used in most areas where there is a need for infection prevention and tissue-friendly properties. We have successfully applied our coating to various types of titanium, stainless steel, latex, silicone, polumers, cermaics and non-woven materials. as the coating is very thin , it does not affect the product’s other properties such as thickness, appearance and stiffness.
There is also significant potential in jointly developing new products and license applications for infection prevention.
9. Profitable growth
Our strong financial results in 2019 show that we are making good progress on our growth journey and there is a lot of potential for additional growth as we move forward. In 2019 revenues increased by more than 20% to almost MSEK 200, while EBITDA trebled with a margin of more than 30%.
Our goal is to achieve an annual revenues growth of 20% per year over a 5-year period with 2015 as the base year, and achieve an EBITDA margin of at least 30% by 2020.
We have a careful finance policy. Our target is to have an equity ratio of at least 30%. In 2019, we established a positive operating cash flow.
Our long-term objective is to distribute 30–50% of profit after tax as dividend, taking into consideration the company’s financial position. However, since we are in an expansion phase we will prioritize growth over dividends in the coming years.
10. Long-term owners and dedicated management
The company’s founders are its main owners and adopt a longterm approach to their ownership. Major Swedish institutions also number among our largest owners. The Board of Directors represents wide-ranging experience from industry, entrepreneurship, clinical research and medical expertise.
The Group management team has extensive experience of the medical device industry as well as sales and marketing. The management team also has experience from major global companies and medical expertise. Everyone in the Board of Directors and in the Group management team owns share in the company.